5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K¦Ä) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B)

详细信息    查看全文

• 作者：Jennifer R. Brown¹ ; Thomas M. Jahn² ; Richard R. Furman³ ; John P. Leonard³ ; Stephen E. Spurgeon⁴ ; John C. Byrd⁵ ; Don M. Benson⁵ ; Steven E. Coutre⁶ ; Nina D. Wagner-Johnston⁷ ; Ian W. Flinn⁸ ; Brad S. Kahl⁹ ; Marshall T. Schreeder¹⁰ ; Sven de Vos¹¹ ; Leanne M. Holes² ; Harriet (Sissy) Peterman² ; Dave M. Johnson² ; Langdon L. Miller²
• 刊名：Clinical Lymphoma Myeloma and Leukemia
• 出版年：2011
• 出版时间：October, 2011
• 年：2011
• 卷：11
• 期：supp_S2
• 页码：S272-S274
• 全文大小：112 K

文摘